 [1m([0morchestrator-aplastic anemia-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE SODIUM increase or decrease the risk of [0m
[34maplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"ALENDRONATE SODIUM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE SODIUM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mALENDRONATE SODIUM[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mALENDRONATE SODIUM[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"What is Alendronate Sodium used for?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"Alendronate Sodium"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: ALENDRONATE SODIUM: clinical_pharmacology: While incorporated in bone matrix, alendronate is not pharmacologically active. Thus, alendronate must be continuously administered to suppress [0m
[31mosteoclasts on newly formed resorption surfaces. Histomorphometry in baboons and rats showed that alendronate treatment reduces bone turnover [0m[1;31m([0m[31mi.e., the number of sites at which bone is remodeled[0m[1;31m)[0m[31m. In[0m
[31maddition, bone formation exceeds bone resorption at these remodeling sites, leading to progressive gains in bone mass. [0m[1;31m12.2[0m[31m Pharmacodynamics Alendronate is a bisphosphonate that binds to bone [0m
[31mhydroxyapatite and specifically inhibits the activity of osteoclasts, the bone-resorbing cells. Alendronate reduces bone resorption with no direct effect on bone formation, although the latter process[0m
[31mis ultimately reduced because bone resorption and formation are coupled during bone turnover. ALENDRONATE SODIUM: clinical_pharmacology: Osteoporosis in Postmenopausal Women Osteoporosis is [0m
[31mcharacterized by low bone mass that leads to an increased risk of fracture. The diagnosis can be confirmed by the finding of low bone mass, evidence of fracture on x-ray, a history of osteoporotic [0m
[31mfracture, or height loss or kyphosis, indicative of vertebral [0m[1;31m([0m[31mspinal[0m[1;31m)[0m[31m fracture. Osteoporosis occurs in both males and females but is most common among women following the menopause, when bone [0m
[31mturnover increases and the rate of bone resorption exceeds that of bone formation. These changes result in progressive bone loss and lead to osteoporosis in a significant proportion of women over age [0m
[1;31m50[0m[31m. Fractures, usually of the spine, hip, and wrist, are the common consequences. From age [0m[1;31m50[0m[31m to age [0m[1;31m90[0m[31m, the risk of hip fracture in white women increases [0m[1;31m50[0m[31m-fold and the risk of vertebral fracture [0m
[1;31m15[0m[31m- to [0m[1;31m30[0m[31m-fold. ALENDRONATE SODIUM: clinical_pharmacology: It is estimated that approximately [0m[1;31m40[0m[31m% of [0m[1;31m50[0m[31m-year-old women will sustain one or more osteoporosis-related fractures of the spine, hip, or [0m
[31mwrist during their remaining lifetimes. Hip fractures, in particular, are associated with substantial morbidity, disability, and mortality. Daily oral doses of alendronate sodium [0m[1;31m([0m[1;31m5[0m[31m, [0m[1;31m20[0m[31m, and [0m[1;31m40[0m[31m mg for[0m
[31msix weeks[0m[1;31m)[0m[31m in postmenopausal women produced biochemical changes indicative of dose-dependent inhibition of bone resorption, including decreases in urinary calcium and urinary markers of bone collagen [0m
[31mdegradation [0m[1;31m([0m[31msuch as deoxypyridinoline and cross-linked N-telopeptides of type I collagen[0m[1;31m)[0m[31m. These biochemical changes tended to return toward baseline values as early as [0m[1;31m3[0m[31m weeks following the [0m
[31mdiscontinuation of therapy with alendronate and did not differ from placebo after [0m[1;31m7[0m[31m months. ALENDRONATE SODIUM: clinical_pharmacology: Long-term treatment of osteoporosis with alendronate sodium [0m[1;31m10[0m[31m [0m
[31mmg/day [0m[1;31m([0m[31mfor up to five years[0m[1;31m)[0m[31m reduced urinary excretion of markers of bone resorption, deoxypyridinoline and cross-linked N-telopeptides of type l collagen, by approximately [0m[1;31m50[0m[31m% and [0m[1;31m70[0m[31m%, respectively,[0m
[31mto reach levels similar to those seen in healthy premenopausal women. Similar decreases were seen in patients in osteoporosis prevention studies who received alendronate sodium [0m[1;31m5[0m[31m mg/day. The decrease [0m
[31min the rate of bone resorption indicated by these markers was evident as early as [0m[1;31m1[0m[31m month and at [0m[1;31m3[0m[31m to [0m[1;31m6[0m[31m months reached a plateau that was maintained for the entire duration of treatment with [0m
[31malendronate sodium. ALENDRONATE SODIUM: clinical_pharmacology: In osteoporosis treatment studies alendronate sodium [0m[1;31m10[0m[31m mg/day decreased the markers of bone formation, osteocalcin and bone specific [0m
[31malkaline phosphatase by approximately [0m[1;31m50[0m[31m%, and total serum alkaline phosphatase by approximately [0m[1;31m25[0m[31m to [0m[1;31m30[0m[31m% to reach a plateau after [0m[1;31m6[0m[31m to [0m[1;31m12[0m[31m months. In osteoporosis prevention studies alendronate [0m
[31msodium [0m[1;31m5[0m[31m mg/day decreased osteocalcin and total serum alkaline phosphatase by approximately [0m[1;31m40[0m[31m% and [0m[1;31m15[0m[31m%, respectively. Similar reductions in the rate of bone turnover were observed in postmenopausal [0m
[31mwomen during one-year studies with once weekly alendronate sodium [0m[1;31m70[0m[31m mg for the treatment of osteoporosis and once weekly alendronate sodium [0m[1;31m35[0m[31m mg for the prevention of osteoporosis. These data [0m
[31mindicate that the rate of bone turnover reached a new steady state, despite the progressive increase in the total amount of alendronate deposited within bone. ALENDRONATE SODIUM: [0m
[31mclinical_pharmacology: As a result of inhibition of bone resorption, asymptomatic reductions in serum calcium and phosphate concentrations were also observed following treatment with alendronate [0m
[31msodium. In the long-term studies, reductions from baseline in serum calcium [0m[1;31m([0m[31mapproximately [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m and phosphate [0m[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m to [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m were evident the first month after the initiation of alendronate [0m
[31msodium [0m[1;31m10[0m[31m mg. No further decreases in serum calcium were observed for the five-year duration of treatment; however, serum phosphate returned toward prestudy levels during years three through five. [0m
[31mSimilar reductions were observed with alendronate sodium [0m[1;31m5[0m[31m mg/day. In one-year studies with once weekly alendronate sodium [0m[1;31m35[0m[31m and [0m[1;31m70[0m[31m mg, similar reductions were observed at [0m[1;31m6[0m[31m and [0m[1;31m12[0m[31m months. The [0m
[31mreduction in serum phosphate may reflect not only the positive bone mineral balance due to alendronate sodium but also a decrease in renal phosphate reabsorption.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: drug_interactions: [0m[1;31m7[0m[31m DRUG INTERACTIONS Calcium supplements, antacids or oral medications containing multivalent cations interfere with absorption of alendronate. [0m[1;31m([0m[31m [0m[1;31m7.1[0m[31m [0m[1;31m)[0m[31m [0m
[31mUse caution when co-prescribing aspirin/nonsteroidal anti- inflammatory drugs that may worsen gastrointestinal irritation. [0m[1;31m([0m[31m [0m[1;31m7.2[0m[31m , [0m[1;31m7.3[0m[31m [0m[1;31m)[0m[31m [0m[1;31m7.1[0m[31m Calcium Supplements/Antacids Co-administration of BINOSTO [0m
[31mand calcium, antacids, or oral medications containing multivalent cations will interfere with absorption of BINOSTO. Therefore, instruct patients to wait at least one-half hour after taking BINOSTO [0m
[31mbefore taking any other oral medications. [0m[1;31m7.2[0m[31m Aspirin In clinical studies, the incidence of upper gastrointestinal adverse events was increased in patients receiving concomitant therapy with daily [0m
[31mdoses of alendronate sodium greater than [0m[1;31m10[0m[31m mg and aspirin-containing products. [0m[1;31m7[0m[31m. ALENDRONATE SODIUM: drug_interactions: [0m[1;31m3[0m[31m Nonsteroidal Anti-inflammatory Drugs [0m[1;31m([0m[31mNSAIDs[0m[1;31m)[0m[31m BINOSTO may be administered to[0m
[31mpatients taking NSAIDs. In a [0m[1;31m3[0m[31m-year, controlled, clinical study [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m2027[0m[1;31m)[0m[31m during which a majority of patients received concomitant NSAIDs, the incidence of upper gastrointestinal adverse events was [0m
[31msimilar in patients taking alendronate sodium [0m[1;31m5[0m[31m or [0m[1;31m10[0m[31m mg/day compared to those taking placebo. However, since NSAID use is associated with gastrointestinal irritation, caution should be used during [0m
[31mconcomitant use with BINOSTO. [0m[1;31m7.4[0m[31m Levothyroxine The bioavailability of alendronate was slightly decreased when BINOSTO and levothyroxine were co-administered to healthy subjects [0m[31m .         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: warnings_and_cautions: [0m[1;31m5[0m[31m WARNINGS AND PRECAUTIONS Upper Gastrointestinal Adverse Reactions can occur. Instruct patients to follow dosing instructions. Discontinue if new [0m
[31mor worsening symptoms occur. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[31m Hypocalcemia can worsen and must be corrected prior to use. [0m[1;31m([0m[31m [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Severe Bone, Joint, Muscle Pain may occur. Discontinue use if severe symptoms develop. [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[31m [0m
[31mOsteonecrosis of the Jaw has been reported. [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[31m Atypical Femur Fractures have been reported. Patients with new thigh or groin pain should be evaluated to rule out a femoral fracture. [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m [0m
[31mSodium Content: Each tablet contains [0m[1;31m603[0m[31m mg sodium, equivalent to [0m[1;31m1532[0m[31m mg NaCl. Use caution in patients on sodium restriction. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5[0m[31m. ALENDRONATE SODIUM: warnings_and_cautions: [0m[1;31m1[0m[31m Upper [0m
[31mGastrointestinal Adverse Reactions BINOSTO, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. Because of these possible irritant effects [0m
[31mand a potential for worsening of the underlying disease, caution should be used when BINOSTO is given to patients with active upper gastrointestinal problems [0m[1;31m([0m[31msuch as known Barrett's esophagus, [0m
[31mdysphagia, other esophageal diseases, gastritis, duodenitis, or ulcers[0m[1;31m)[0m[31m. Esophageal adverse experiences, such as esophagitis, esophageal ulcers and esophageal erosions, occasionally with bleeding and [0m
[31mrarely followed by esophageal stricture or perforation, have been reported in patients receiving treatment with oral bisphosphonates including alendronate sodium. In some cases these have been severe [0m
[31mand required hospitalization. ALENDRONATE SODIUM: warnings_and_cautions: Physicians should therefore be alert to any signs or symptoms signaling a possible esophageal reaction and patients should be [0m
[31minstructed to discontinue BINOSTO and seek medical attention if they develop dysphagia, odynophagia, retrosternal pain or new or worsening heartburn. The risk of severe esophageal adverse experiences [0m
[31mappears to be greater in patients who lie down after taking oral bisphosphonates including alendronate sodium, and/or who continue to take oral bisphosphonates including alendronate sodium after [0m
[31mdeveloping symptoms suggestive of esophageal irritation. Therefore, it is very important that the full dosing instructions are provided to, and understood by, the patient [0m[31m . In patients who cannot [0m
[31mcomply with dosing instructions due to mental disability, therapy with BINOSTO should be used under appropriate supervision. ALENDRONATE SODIUM: warnings_and_cautions: There have been post-marketing [0m
[31mreports of gastric and duodenal ulcers with oral bisphosphonate use, some severe and with complications, although no increased risk was observed in controlled clinical trials [0m[31m . [0m[1;31m5.2[0m[31m Mineral Metabolism[0m
[31mHypocalcemia must be corrected before initiating therapy with BINOSTO [0m[31m. Other disorders affecting mineral metabolism [0m[1;31m([0m[31msuch as vitamin D deficiency[0m[1;31m)[0m[31m should also be effectively treated. In patients with[0m
[31mthese conditions, serum calcium and symptoms of hypocalcemia should be monitored during therapy with BINOSTO. Presumably due to the effects of BINOSTO on increasing bone mineral, small, asymptomatic [0m
[31mdecreases in serum calcium and phosphate may occur. Patients should receive adequate calcium and vitamin D intake. [0m[1;31m5[0m[31m. ALENDRONATE SODIUM: warnings_and_cautions: [0m[1;31m3[0m[31m Musculoskeletal Pain In [0m
[31mpost-marketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain has been reported in patients taking bisphosphonates that are approved for the treatment of [0m
[31mosteoporosis [0m[31m . This category of drugs includes BINOSTO. Most of the patients were postmenopausal women. The time to onset of symptoms varied from one day to several months after starting the drug. [0m
[31mDiscontinue use if severe symptoms develop. Most patients had relief of symptoms after stopping. A subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate. In [0m
[31mplacebo-controlled clinical studies of alendronate sodium, the percentages of patients with these symptoms were similar in the alendronate sodium and placebo groups. [0m[1;31m5[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: use_in_specific_populations: [0m[1;31m8[0m[31m USE IN SPECIFIC POPULATIONS Pregnancy: Discontinue when pregnancy is recognized. [0m[1;31m([0m[31m [0m[1;31m8.1[0m[31m [0m[1;31m)[0m[31m BINOSTO is not indicated for use in pediatric [0m
[31mpatients. [0m[1;31m([0m[31m [0m[1;31m8.4[0m[31m [0m[1;31m)[0m[31m BINOSTO is not recommended in patients with renal impairment [0m[1;31m([0m[31mcreatinine clearance less than [0m[1;31m35[0m[31m mL/min[0m[1;31m)[0m[31m. [0m[1;31m([0m[31m [0m[1;31m5.6[0m[31m , [0m[1;31m8.6[0m[31m [0m[1;31m)[0m[31m [0m[1;31m8.1[0m[31m Pregnancy Risk Summary Available data on the use of BINOSTO[0m
[31min pregnant women are insufficient to inform a drug-associated risk of adverse maternal or fetal outcomes. Discontinue BINOSTO when pregnancy is recognized. In animal reproduction studies, daily oral [0m
[31madministration of alendronate to rats from before mating through the end of gestation or lactation showed decreased postimplantation survival and decreased pup body weight gain starting at doses [0m
[31mequivalent to less than half of the highest recommended [0m[1;31m40[0m[31m mg clinical daily dose [0m[1;31m([0m[31mbased on body surface area, mg/m [0m[1;31m2[0m[31m [0m[1;31m)[0m[31m. ALENDRONATE SODIUM: use_in_specific_populations: Oral administration of [0m
[31malendronate to rats during organogenesis resulted in reduced fetal ossification starting at doses [0m[1;31m3[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose. No similar fetal effects were observed in pregnant rabbits [0m
[31mdosed orally during organogenesis at doses equivalent to approximately [0m[1;31m10[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose. Delayed or failed delivery of offspring, protracted parturition, and late pregnancy [0m
[31mmaternal and fetal deaths due to maternal hypocalcemia occurred in rats at oral doses as low as one tenth the [0m[1;31m40[0m[31m mg clinical daily dose [0m[1;31m([0m[31mSee Data [0m[1;31m)[0m[31m. Bisphosphonates are incorporated into the bone [0m
[31mmatrix, from which they are gradually released over a period of years. The amount of bisphosphonate incorporated into adult bone and available for release into the systemic circulation is directly [0m
[31mrelated to the dose and duration of bisphosphonate use. ALENDRONATE SODIUM: use_in_specific_populations: Consequently, based on the mechanism of action of bisphosphonates, there is a potential risk of[0m
[31mfetal harm, predominantly skeletal, if a woman becomes pregnant after completing a course of bisphosphonate therapy. The impact of variables such as time between cessation of bisphosphonate therapy to[0m
[31mconception, the particular bisphosphonate used, and the route of administration [0m[1;31m([0m[31mintravenous versus oral[0m[1;31m)[0m[31m on the risk has not been studied. The estimated background risk of major birth defects and [0m
[31mmiscarriage for the indicated [0m[1;31mpopulation[0m[1;31m([0m[31ms[0m[1;31m)[0m[31m is unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated [0m
[31mbackground risks of major birth defects and miscarriage in clinically recognized pregnancies is [0m[1;31m2[0m[31m-[0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m-[0m[1;31m20[0m[31m%, respectively. ALENDRONATE SODIUM: use_in_specific_populations: Data Animal Data [0m
[31mReproduction studies in rats dosed orally from before mating to the end of gestation or lactation showed decreased postimplantation survival starting at [0m[1;31m2[0m[31m mg/kg/day and decreased body weight gain [0m
[31mstarting at [0m[1;31m1[0m[31m mg/kg/day, doses equivalent to less than half the [0m[1;31m40[0m[31m mg clinical daily dose based on body surface area, mg/m [0m[1;31m2[0m[31m . Incidence of incomplete fetal ossification in vertebral, skull, and [0m
[31msternebral bones were increased in rats dosed orally during organogenesis starting at [0m[1;31m10[0m[31m mg/kg/day [0m[1;31m([0m[31mapproximately [0m[1;31m3[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. No similar fetal effects were observed in [0m
[31mpregnant rabbits dosed orally during organogenesis at up to [0m[1;31m35[0m[31m mg/kg/day [0m[1;31m([0m[31mequivalent to approximately [0m[1;31m10[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. ALENDRONATE SODIUM: use_in_specific_populations: Both [0m
[31mtotal and ionized calcium decreased in pregnant rats dosed orally with [0m[1;31m15[0m[31m mg/kg/day alendronate [0m[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m resulting in delays and failures of delivery. [0m
[31mProtracted parturition due to maternal hypocalcemia was observed when rats were treated from before mating through gestation starting at [0m[1;31m0.5[0m[31m mg/kg/day [0m[1;31m([0m[31mapproximately one tenth the [0m[1;31m40[0m[31m mg clinical daily[0m
[31mdose[0m[1;31m)[0m[31m. Maternotoxicity [0m[1;31m([0m[31mlate pregnancy deaths[0m[1;31m)[0m[31m also occurred in female rats treated orally with [0m[1;31m15[0m[31m mg/kg/day [0m[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m for varying gestational time periods.[0m
[31mThese maternal deaths were lessened but not eliminated by cessation of treatment. Calcium supplementation in the drinking water or by subcutaneous minipump to rats dosed orally with [0m[1;31m15[0m[31m mg/kg/day [0m
[31malendronate could not ameliorate the hypocalcemia or prevent the dystocia-related maternal and neonatal deaths. ALENDRONATE SODIUM: use_in_specific_populations: However, intravenous calcium [0m
[31msupplementation prevented maternal, but not neonatal deaths. [0m[1;31m8.2[0m[31m Lactation Risk Summary It is not known whether alendronate is present in human breast milk, affects human milk production, or has [0m
[31meffects on the breastfed infant. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for BINOSTO and any potential adverse effects on the [0m
[31mbreastfed child from BINOSTO or from the underlying maternal condition. [0m[1;31m8.4[0m[31m Pediatric Use BINOSTO is not indicated for use in pediatric patients. The safety and efficacy of alendronate sodium were [0m
[31mexamined in a randomized, double-blind, placebo-controlled two-year study of [0m[1;31m139[0m[31m pediatric patients, aged [0m[1;31m4[0m[31m-[0m[1;31m18[0m[31m years, with severe osteogenesis imperfecta [0m[1;31m([0m[31mOI[0m[1;31m)[0m[31m. ALENDRONATE SODIUM: [0m
[31muse_in_specific_populations: One-hundred-and-nine patients were randomized to [0m[1;31m5[0m[31m mg alendronate sodium daily [0m[1;31m([0m[31mweight less than [0m[1;31m40[0m[31m kg[0m[1;31m)[0m[31m or [0m[1;31m10[0m[31m mg alendronate sodium daily [0m[1;31m([0m[31mweight greater than or equal to [0m
[1;31m40[0m[31m kg[0m[1;31m)[0m[31m and [0m[1;31m30[0m[31m patients to placebo. The mean baseline lumbar spine BMD Z-score of the patients was [0m[1;31m-4.5[0m[31m. The mean change in lumbar spine BMD Z-score from baseline to Month [0m[1;31m24[0m[31m was [0m[1;31m1.3[0m[31m in the [0m
[31malendronate-treated patients and [0m[1;31m0.1[0m[31m in the placebo- treated patients. Treatment with alendronate sodium did not reduce the risk of fracture. Sixteen percent of the alendronate-treated patients who [0m
[31msustained a radiologically-confirmed fracture by Month [0m[1;31m12[0m[31m of the study had delayed fracture healing [0m[1;31m([0m[31mcallus remodeling[0m[1;31m)[0m[31m or fracture non-union when assessed radiographically at Month [0m[1;31m24[0m[31m compared with [0m
[1;31m9[0m[31m% of the placebo-treated patients. ALENDRONATE SODIUM: use_in_specific_populations: In alendronate-treated patients, bone histomorphometry data obtained at Month [0m[1;31m24[0m[31m demonstrated decreased bone [0m
[31mturnover and delayed mineralization time; however, there were no mineralization defects. There were no statistically significant differences between the alendronate sodium and placebo groups in [0m
[31mreduction of bone pain. The oral bioavailability in children was similar to that observed in adults. The overall safety profile of alendronate sodium in osteogenesis imperfecta patients treated for up[0m
[31mto [0m[1;31m24[0m[31m months was generally similar to that of adults with osteoporosis treated with alendronate sodium. However, there was an increased occurrence of vomiting in osteogenesis imperfecta patients [0m
[31mtreated with alendronate sodium compared to placebo. During the [0m[1;31m24[0m[31m-month treatment period, vomiting was observed in [0m[1;31m32[0m[31m of [0m[1;31m109[0m[31m [0m[1;31m([0m[1;31m29.4[0m[31m%[0m[1;31m)[0m[31m patients treated with alendronate sodium and [0m[1;31m3[0m[31m of [0m[1;31m30[0m[31m [0m[1;31m([0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m [0m
[31mpatients treated with placebo. ALENDRONATE SODIUM: use_in_specific_populations: In a pharmacokinetic study, [0m[1;31m6[0m[31m of [0m[1;31m24[0m[31m pediatric osteogenesis imperfecta patients who received a single oral dose of [0m
[31malendronate sodium [0m[1;31m35[0m[31m or [0m[1;31m70[0m[31m mg developed fever, flu-like symptoms, and/or mild lymphocytopenia within [0m[1;31m24[0m[31m to [0m[1;31m48[0m[31m hours after administration. These events, lasting no more than [0m[1;31m2[0m[31m to [0m[1;31m3[0m[31m days and responding[0m
[31mto acetaminophen, are consistent with an acute-phase response that has been reported in patients receiving bisphosphonates, including alendronate sodium. [0m[1;31m[[0m[31mSee Adverse Reactions [0m[1;31m([0m[1;31m6.2[0m[1;31m)[0m[31m .[0m[1;31m][0m[31m [0m[1;31m8.5[0m[31m Geriatric [0m
[31mUse Of the patients receiving alendronate sodium in the Fracture Intervention Trial [0m[1;31m([0m[31mFIT[0m[1;31m)[0m[31m, [0m[1;31m71[0m[31m% [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m2302[0m[1;31m)[0m[31m were greater than or equal to [0m[1;31m65[0m[31m years of age and [0m[1;31m17[0m[31m% [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m550[0m[1;31m)[0m[31m were greater than or equal to [0m[1;31m75[0m[31m [0m
[31myears of age. ALENDRONATE SODIUM: use_in_specific_populations: Of the patients receiving alendronate sodium in the United States and Multinational osteoporosis treatment studies in women and [0m
[31mosteoporosis studies in men, [0m[31m , [0m[1;31m45[0m[31m% and [0m[1;31m54[0m[31m%, respectively, were [0m[1;31m65[0m[31m years of age or over. No overall differences in efficacy or safety were observed between these patients and younger patients, but [0m
[31mgreater sensitivity of some older individuals cannot be ruled out. [0m[1;31m8.6[0m[31m Renal Impairment BINOSTO is not recommended for patients with creatinine clearance less than [0m[1;31m35[0m[31m mL/min . No dosage adjustment is [0m
[31mnecessary in patients with creatinine clearance values between [0m[1;31m35[0m[31m-[0m[1;31m60[0m[31m mL/min [0m[31m . [0m[1;31m8.7[0m[31m Hepatic Impairment As there is evidence that alendronate is not metabolized or excreted in the bile, no studies were [0m
[31mconducted in patients with hepatic impairment. ALENDRONATE SODIUM: use_in_specific_populations: No dosage adjustment is necessary [0m[31m .         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: clinical_studies: [0m[1;31m5[0m[31m [0m[1;31m78[0m[31m [0m[31mp[0m[31m=[0m[1;31m0[0m[1;31m.035[0m[31m, Clinical [0m[1;31m([0m[31msymptomatic[0m[1;31m)[0m[31m fractures Any clinical [0m[1;31m([0m[31msymptomatic[0m[1;31m)[0m[31m fracture [0m[1;31m12.9[0m[31m [0m[1;31m16.2[0m[31m [0m[1;31m3.3[0m[31m [0m[1;31m22[0m[31m [0m[31mp[0m[31m=[0m[1;31m0[0m[1;31m.01[0m[31m ≥[0m[1;31m1[0m[31m clinical [0m[1;31m([0m[31msymptomatic[0m[1;31m)[0m[31m vertebral fracture [0m
[1;31m1.0[0m[31m [0m[1;31m1.6[0m[31m [0m[1;31m0.6[0m[31m [0m[1;31m41[0m[1;31m([0m[31mNS[0m[1;31m)[0m[31m Not significant. This study was not powered to detect differences at these sites. Hip fracture [0m[1;31m1.0[0m[31m [0m[1;31m1.4[0m[31m [0m[1;31m0.4[0m[31m [0m[1;31m29[0m[1;31m([0m[31mNS[0m[1;31m)[0m[31m Wrist [0m[1;31m([0m[31mforearm[0m[1;31m)[0m[31m fracture [0m[1;31m3.9[0m[31m [0m[1;31m3.8[0m[31m [0m[1;31m-0.1[0m[31m NS Fracture Results Across [0m
[31mStudies In the Three-Year Study of FIT, alendronate sodium reduced the percentage of women experiencing at least one new radiographic vertebral fracture from [0m[1;31m15.0[0m[31m% to [0m[1;31m7.9[0m[31m% [0m[1;31m([0m[1;31m47[0m[31m% relative risk [0m
[31mreduction, p<[0m[1;31m0.001[0m[1;31m)[0m[31m; in the Four-Year Study of FIT, the percentage was reduced from [0m[1;31m3[0m[31m. ALENDRONATE SODIUM: clinical_studies: [0m[1;31m8[0m[31m% to [0m[1;31m2.1[0m[31m% [0m[1;31m([0m[1;31m44[0m[31m% relative risk reduction, [0m[31mp[0m[31m=[0m[1;31m0[0m[1;31m.001[0m[1;31m)[0m[31m; and in the combined [0m
[31mU.S.[0m[31m/[0m[31mMultinational[0m[31m studies, from [0m[1;31m6.2[0m[31m% to [0m[1;31m3.2[0m[31m% [0m[1;31m([0m[1;31m48[0m[31m% relative risk reduction, [0m[31mp[0m[31m=[0m[1;31m0[0m[1;31m.034[0m[1;31m)[0m[31m. Alendronate sodium reduced the percentage of women experiencing multiple [0m[1;31m([0m[31mtwo or more[0m[1;31m)[0m[31m new vertebral fractures [0m
[31mfrom [0m[1;31m4.2[0m[31m% to [0m[1;31m0.6[0m[31m% [0m[1;31m([0m[1;31m87[0m[31m% relative risk reduction, p<[0m[1;31m0.001[0m[1;31m)[0m[31m in the combined U.S.[0m[31m/[0m[31mMultinational[0m[31m studies and from [0m[1;31m4.9[0m[31m% to [0m[1;31m0.5[0m[31m% [0m[1;31m([0m[1;31m90[0m[31m% relative risk reduction, p<[0m[1;31m0.001[0m[1;31m)[0m[31m in the Three-Year Study of FIT. In the [0m
[31mFour-Year Study of FIT, alendronate sodium reduced the percentage of osteoporotic women experiencing multiple vertebral fractures from [0m[1;31m0.6[0m[31m% to [0m[1;31m0.1[0m[31m% [0m[1;31m([0m[1;31m78[0m[31m% relative risk reduction, [0m[31mp[0m[31m=[0m[1;31m0[0m[1;31m.035[0m[1;31m)[0m[31m. ALENDRONATE [0m
[31mSODIUM: clinical_studies: Thus, alendronate sodium reduced the incidence of radiographic vertebral fractures in osteoporotic women whether or not they had a previous radiographic vertebral fracture. [0m
[31mEffect on Bone Mineral Density The bone mineral density efficacy of alendronate sodium [0m[1;31m10[0m[31m mg once daily in postmenopausal women, [0m[1;31m44[0m[31m to [0m[1;31m84[0m[31m years of age, with osteoporosis [0m[1;31m([0m[31mlumbar spine bone mineral [0m
[31mdensity [0m[1;31m[[0m[31mBMD[0m[1;31m][0m[31m of at least [0m[1;31m2[0m[31m standard deviations below the premenopausal mean[0m[1;31m)[0m[31m was demonstrated in [0m[1;31m4[0m[31m double-blind, placebo-controlled clinical studies of [0m[1;31m2[0m[31m or [0m[1;31m3[0m[31m years' duration. Figure [0m[1;31m2[0m[31m shows the mean[0m
[31mincreases in BMD of the lumbar spine, femoral neck, and trochanter in patients receiving alendronate sodium [0m[1;31m10[0m[31m mg/day relative to placebo-treated patients at three years for each of these studies. [0m
[31mALENDRONATE SODIUM: clinical_studies: Figure [0m[1;31m2[0m[31m Osteoporosis Treatment Studies in Postmenopausal Women Increase in BMD Alendronate Sodium [0m[1;31m10[0m[31m mg/day at Three Years At [0m[1;31m3[0m[31m years significant increases in [0m
[31mBMD, relative both to baseline and placebo, were seen at each measurement site in each study in patients who received alendronate [0m[1;31m10[0m[31m mg/day. Total body BMD also increased significantly in each study, [0m
[31msuggesting that the increases in bone mass of the spine and hip did not occur at the expense of other skeletal sites. Increases in BMD were evident as early as [0m[1;31m3[0m[31m months and continued throughout the [0m[1;31m3[0m[31m [0m
[31myears of treatment. [0m[1;31m([0m[31m See figures below for lumbar spine results.[0m[1;31m)[0m[31m In the [0m[1;31m2[0m[31m-year extension of these studies, treatment of [0m[1;31m147[0m[31m patients with alendronate sodium [0m[1;31m10[0m[31m mg/day resulted in continued increases[0m
[31min BMD at the lumbar spine and trochanter [0m[1;31m([0m[31mabsolute additional increases between years [0m[1;31m3[0m[31m and [0m[1;31m5[0m[31m: lumbar spine, [0m[1;31m0[0m[31m. ALENDRONATE SODIUM: clinical_studies: [0m[1;31m94[0m[31m%; trochanter, [0m[1;31m0.88[0m[31m%[0m[1;31m)[0m[31m. BMD at the femoral neck,[0m
[31mforearm and total body were maintained. Alendronate sodium was similarly effective regardless of age, race, baseline rate of bone turnover, and baseline BMD in the range studied [0m[1;31m([0m[31mat least [0m[1;31m2[0m[31m standard [0m
[31mdeviations below the premenopausal mean[0m[1;31m)[0m[31m. Figure [0m[1;31m3[0m[31m Osteoporosis Treatment in Studies in Postmenopausal Women Time Course Effect of Alendronate Sodium [0m[1;31m10[0m[31m mg/day Versus Placebo: Lumbar Spine BMD Percent[0m
[31mChange From Baseline In patients with postmenopausal osteoporosis treated with alendronate sodium [0m[1;31m10[0m[31m mg/day for one or two years, the effects of treatment withdrawal were assessed. Following [0m
[31mdiscontinuation, there were no further increases in bone mass and the rates of bone loss were similar to those of the placebo groups. ALENDRONATE SODIUM: clinical_studies: Figure [0m[1;31m2[0m[31m Figure [0m[1;31m3[0m[31m Bone [0m
[31mHistology Bone histology in [0m[1;31m270[0m[31m postmenopausal patients with osteoporosis treated with alendronate sodium at doses ranging from [0m[1;31m1[0m[31m to [0m[1;31m20[0m[31m mg/day for one, two, or three years revealed normal [0m
[31mmineralization and structure, as well as the expected decrease in bone turnover relative to placebo. These data, together with the normal bone histology and increased bone strength observed in rats [0m
[31mand baboons exposed to long-term alendronate treatment, support the conclusion that bone formed during therapy with alendronate sodium is of normal quality. Effect on height Alendronate sodium, over a[0m
[31mthree- or four-year period, was associated with statistically significant reductions in loss of height vs. placebo in patients with and without baseline radiographic vertebral fractures. At the end of[0m
[31mthe FIT studies the between-treatment group differences were [0m[1;31m3.2[0m[31m mm in the Three-Year Study and [0m[1;31m1.3[0m[31m mm in the Four-Year Study. ALENDRONATE SODIUM: clinical_studies: Weekly dosing The therapeutic [0m
[31mequivalence of once weekly alendronate sodium [0m[1;31m70[0m[31m mg [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m519[0m[1;31m)[0m[31m and alendronate sodium [0m[1;31m10[0m[31m mg daily [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m370[0m[1;31m)[0m[31m was demonstrated in a one-year, double-blind, multicenter study of postmenopausal women with [0m
[31mosteoporosis. In the primary analysis of completers, the mean increases from baseline in lumbar spine BMD at [0m[1;31m1[0m[31m year were [0m[1;31m5.1[0m[31m% [0m[1;31m([0m[1;31m4.8[0m[31m, [0m[1;31m5.4[0m[31m%; [0m[1;31m95[0m[31m% CI[0m[1;31m)[0m[31m in the [0m[1;31m70[0m[31m mg once-weekly group [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m440[0m[1;31m)[0m[31m and [0m[1;31m5.4[0m[31m% [0m[1;31m([0m[1;31m5.0[0m[31m, [0m
[1;31m5.8[0m[31m%; [0m[1;31m95[0m[31m% CI[0m[1;31m)[0m[31m in the [0m[1;31m10[0m[31m mg daily group [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m330[0m[1;31m)[0m[31m. The [0m[1;31m2[0m[31m treatment groups were also similar with regard to BMD increases at other skeletal sites. The results of the intention-to-treat analysis were [0m
[31mconsistent with the primary analysis of completers. [0m[1;31m14[0m[31m. ALENDRONATE SODIUM: clinical_studies: [0m[1;31m2[0m[31m Treatment to Increase Bone Mass in Men with Osteoporosis The efficacy of alendronate sodium in men with [0m
[31mhypogonadal or idiopathic osteoporosis was demonstrated in two clinical studies. Daily Dosing A two-year, double-blind, placebo-controlled, multicenter study of alendronate sodium [0m[1;31m10[0m[31m mg once daily [0m
[31menrolled a total of [0m[1;31m241[0m[31m men between the ages of [0m[1;31m31[0m[31m and [0m[1;31m87[0m[31m [0m[1;31m([0m[31mmean, [0m[1;31m63[0m[1;31m)[0m[31m. All patients in the trial had either: [0m[1;31m1[0m[1;31m)[0m[31m a BMD T-score less than or equal to [0m[1;31m-2[0m[31m at the femoral neck and less than or equal to [0m[1;31m-1[0m[31m [0m
[31mat the lumbar spine, or [0m[1;31m2[0m[1;31m)[0m[31m a baseline osteoporotic fracture and a BMD T-score less than or equal to [0m[1;31m-1[0m[31m at the femoral neck. At two years, the mean increases relative to placebo in BMD in men receiving[0m
[31malendronate sodium [0m[1;31m10[0m[31m mg/day were significant at the following sites: lumbar spine, [0m[1;31m5[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Alendronate Sodium is used for the treatment and prevention of osteoporosis in postmenopausal women. It works by binding to bone hydroxyapatite and specifically inhibiting the activity of [0m
[32mosteoclasts, the bone-resorbing cells. This reduces bone resorption without directly affecting bone formation, although bone formation is ultimately reduced because bone resorption and formation are [0m
[32mcoupled during bone turnover. Alendronate Sodium is continuously administered to suppress osteoclasts on newly formed resorption surfaces, leading to progressive gains in bone mass.[0m

[32mSOURCE: ALENDRONATE SODIUM label[0m
[32mEXTRACT_START_END: ALENDRONATE SODIUM: clinical_pharmacology: Osteoporosis in Postmenopausal Women Osteoporosis is characterized by[0m[32m...[0m[32mduring their remaining lifetimes.[0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE SODIUM[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Alendronate Sodium is used for the treatment and [0m
[34mprevention of osteoporosis in postmenopausal women. It works by binding to bone hydroxyapatite and specifically inhibiting the activity of osteoclasts, the bone-resorbing cells. This reduces bone [0m
[34mresorption without directly affecting bone formation, although bone formation is ultimately reduced because bone resorption and formation are coupled during bone turnover. Alendronate Sodium is [0m
[34mcontinuously administered to suppress osteoclasts on newly formed resorption surfaces, leading to progressive gains in bone mass.[0m

[34mSOURCE: ALENDRONATE SODIUM label[0m
[34mEXTRACT_START_END: ALENDRONATE SODIUM: clinical_pharmacology: Osteoporosis in Postmenopausal Women Osteoporosis is characterized by[0m[34m...[0m[34mduring their remaining lifetimes.[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of aplastic anemia?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE SODIUM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE SODIUM increase or decrease the risk of [0m
[32maplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE SODIUM increase or decrease the risk of aplastic anemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does Alendronate Sodium increase the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"Alendronate Sodium"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does Alendronate Sodium increase the risk of [0m
[31maplastic anemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE SODIUM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE SODIUM[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE SODIUM[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-aplastic anemia-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mThe FDA label for Alendronate Sodium does not specify [0m
[32minformation regarding the risk of aplastic anemia. Therefore, it is not possible to determine from this source whether Alendronate Sodium increases or decreases the risk of aplastic anemia. [0m

[1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe justification for this answer is that the FDA label for Alendronate Sodium, as provided by FDAHandler, does not contain information about the drug's effect on the risk of aplastic anemia. Without [0m
[32mspecific information from the FDA label, we cannot ascertain the relationship between Alendronate Sodium and the risk of aplastic anemia.[0m
